Safety and efficacy of RT002, an injectable botulinum toxin type A, for treating glabellar lines: Results of a phase 1/2, open-label, sequential dose-escalation study

Dermatologic Surgery

Volumn 41, Issue , 2015, Pages S47-S55

  Garcia Murray, Enrique ^a   Velasco Villasenor, María Luisa ^a   Acevedo, Berenice ^a   Luna, Silvia ^a   Lee, Jane ^b   Waugh, Jacob M ^b   Hornfeldt, Carl S ^b  

^a Private Clinic   (Mexico)

^b Revance Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; RT 002; UNCLASSIFIED DRUG; MUSCLE RELAXANT AGENT; RT002 BOTULINUM TOXIN;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; ESTHETICS; FACIES; FEMALE; FOLLOW UP; GLABELLAR LINE; GLABELLAR LINE SEVERITY SCALE; HUMAN; INJECTION SITE; INJECTION SITE BURNING; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; MALE; MEDICAL PHOTOGRAPHY; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; WRINKLE; CHEMICALLY INDUCED; CLINICAL TRIAL; CUTANEOUS PARAMETERS; DRUG EFFECTS; FOREHEAD; HEADACHE; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; PAIN; PRURITUS;

ADULT; BOTULINUM TOXINS, TYPE A; FEMALE; FOREHEAD; HEADACHE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PAIN; PRURITUS; SKIN AGING;

EID: 84920722410     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1097/DSS.0000000000000276     Document Type: Article

References (24)

1. Allergan Inc. Botox Cosmetic (onabotulinumtoxinA) for injection prescribing information. Allergan Inc.: Invine, 2009.
2. Medicis Aesthetics, Inc. Dysport for injection (abobotulinumtoxinA) prescribing information. Medicis Aesthetics, Inc.: Scottsdale, 2009.
3. Merz Pharmaceuticals, LLC. XEOMIN (incobotulinumtoxinA) for injection prescribing information. Merz Pharmaceuticals, LLC: Greensboro, 2011.
4. Klein A. Contraindications and complications with the use of botulinum toxin. Clin Dermatol 2003;22:66-75.
5. Singh GC, Hankins MC, Dulku A, Kelly MB. Psychosocial aspects of botox in aesthetic surgery. Aesthetic Plast Surg 2006;30:71-6.
6. Carruthers JA, Lowe NJ, Menter MA, Gibson J, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002;46:840-9.
7. Carruthers J, Lowe N, Menter M, Gibson J, et al. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 2003;112:1089-98.
8. Rubin M, Dover J, Glogau R, Goldberg DJ, et al. The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. J Drugs Dermatol 2009;8:439-44.
9. Brandt F, Swanson N, Baumann L, Huber B. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatol Surg 2009;35:1893-901.
10. Kassir R, Kolluru A, Kassir M. Triple-blind, prospective, internally controlled comparative study between abobotulinumtoxinA and onabotulinumtoxinA for the treatment of facial rhytids. Dermatol Ther (Heidelb) 2013;3:179-89.
11. Prager W, Bee EK, Havermann I, Zschocke I. Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-Arm, prospective clinical study. Clin Interv Aging 2013;8:449-56.
12. Stone HF, Zhu Z, Thach TQ, Ruegg CL. Characterization of diffusion and duration of action of a new botulinum toxin type A formulation. Toxicon 2011;58:159-67.
13. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonized tripartite guideline: guideline for good clinical practice. J Postgrad Med 2001;47:45-50.
14. Kane MA, Brandt F, Rohrich RJ, et al. Evaluation of variable-dose treatment with a new U.S. Botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, place-controlled study. Plast Reconstr Surg 2009;124:1619-29.
15. Moy R, Maas C, Monheit G, Huber MB, et al. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg 2009;11:77-83.
16. Bates BA. Guide to physical examination and history taking. 6th ed. Lippincott: Philadelphia, 1997.
17. Yen T, Driscoll C, Lalwani A. Significance of House-Brackmann facial nerve grading global score in the setting of differential facial nerve function. Otol Neurotol 2003;24:118-22.
18. Paternostro-Sluga T, Grim-Stieger M, Posch M, Schuhfried O, et al. Reliability and validity of the Medical Research Council (MRC) scale and a modified scale for testing muscle strength in patients with radial palsy. J Rehabil Med 2008;40:665-71.
19. Cancer therapy evaluation program-common terminology criteria for adverse events version 4.03 (CTEP 2014). Available from: http://ctep. cancer.gov/protocolDevelopment/electronic-Applications/ctc.htm. Accessed March 25, 2014.
20. Flynn TC. Botulinum toxin: examining duration of effect in facial aesthetic applications. Am J Clin Dermatol 2010;11:183-99.
21. Rappl T, Parvizi D, Friedl H, Schuhfried O, et al. Onset and duration of effect of incobotulinumtoxin A, onabotulinumtoxin A, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clin Cosmet Investig Dermatol 2013; 6:211-9.
22. Glogau R, Blitzer A, Brandt F, Kane M, et al. Results of a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a botulinum toxin type A topical gel for the treatment of moderate-to-severe lateral canthal lines. J Drugs Dermatol 2012;11:38-45.
23. Brandt F, O'Connell C, Cazzaniga A, Waugh JM. Efficacy and safety evaluation of a novel botulinum toxin topical gel for the treatment of moderate to severe lateral canthal lines. Dermatol Surg 2010;36: 2111-8.
24. Waugh JM, Lee J, Dake MD, Browne D. Nonclinical and clinical experiences with CPP-based self-Assembling peptide systems in topical drug development. Methods Mol Biol 2011;683:553-72.